Hoth Therapeutics (HOTH) Competitors $1.34 +0.01 (+0.75%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.33 -0.01 (-0.82%) As of 05:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. IRD, ZIVO, RPTX, INKT, COEP, KALA, MNOV, GNTA, INMB, and CUEShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Opus Genetics (IRD), ZIVO Bioscience (ZIVO), Repare Therapeutics (RPTX), MiNK Therapeutics (INKT), Coeptis Therapeutics (COEP), KALA BIO (KALA), MediciNova (MNOV), Genenta Science (GNTA), INmune Bio (INMB), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Its Competitors Opus Genetics ZIVO Bioscience Repare Therapeutics MiNK Therapeutics Coeptis Therapeutics KALA BIO MediciNova Genenta Science INmune Bio Cue Biopharma Hoth Therapeutics (NASDAQ:HOTH) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the media refer more to HOTH or IRD? In the previous week, Hoth Therapeutics and Hoth Therapeutics both had 6 articles in the media. Opus Genetics' average media sentiment score of 0.49 beat Hoth Therapeutics' score of -0.51 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hoth Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Negative Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate HOTH or IRD? Hoth Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 198.51%. Opus Genetics has a consensus target price of $7.33, indicating a potential upside of 472.92%. Given Opus Genetics' higher possible upside, analysts clearly believe Opus Genetics is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, HOTH or IRD? Hoth Therapeutics has higher earnings, but lower revenue than Opus Genetics. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$8.19M-$1.07-1.25Opus Genetics$10.99M6.98-$57.53M-$1.92-0.67 Do insiders and institutionals have more ownership in HOTH or IRD? 7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 6.9% of Hoth Therapeutics shares are held by insiders. Comparatively, 6.6% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is HOTH or IRD more profitable? Hoth Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Hoth Therapeutics' return on equity of -114.32% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -114.32% -105.92% Opus Genetics -377.89%-384.33%-148.90% Which has more volatility & risk, HOTH or IRD? Hoth Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. SummaryHoth Therapeutics beats Opus Genetics on 7 of the 12 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.64M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-1.2520.8975.7826.43Price / SalesN/A458.96546.96119.09Price / CashN/A44.5237.0558.92Price / Book1.569.9311.146.06Net Income-$8.19M-$53.38M$3.29B$266.28M7 Day Performance15.52%0.63%0.16%-0.32%1 Month Performance-2.90%6.31%6.26%3.44%1 Year Performance6.35%11.63%54.63%23.11% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics2.6229 of 5 stars$1.34+0.8%$4.00+198.5%+88.8%$17.64MN/A-1.254IRDOpus Genetics1.9249 of 5 stars$1.15flat$7.33+537.7%N/A$68.89M$10.99M-0.6014News CoverageZIVOZIVO Bioscience0.0688 of 5 stars$18.00+4.7%N/A+49.8%$68.71M$15.85K-3.6910Gap DownRPTXRepare Therapeutics3.4907 of 5 stars$1.58-0.6%$4.50+184.8%-39.0%$68.31M$250K-0.61180News CoverageHigh Trading VolumeINKTMiNK Therapeutics1.7744 of 5 stars$14.57-2.2%$37.50+157.4%+72.0%$67.39MN/A-5.0630Negative NewsShort Interest ↑COEPCoeptis Therapeutics1.4614 of 5 stars$13.65+1.4%N/A+203.2%$64.88MN/A-2.352Short Interest ↓KALAKALA BIO2.8696 of 5 stars$8.78-4.7%$13.00+48.1%+141.4%$64.66M$3.89M-1.2930News CoverageAnalyst UpgradeMNOVMediciNova1.9347 of 5 stars$1.32+0.6%$7.00+430.3%-24.0%$64.37M$1M-5.2810Gap UpGNTAGenenta Science2.7635 of 5 stars$3.50-0.4%$25.00+615.3%-13.6%$64.20MN/A0.007Gap DownHigh Trading VolumeINMBINmune Bio2.2048 of 5 stars$2.24-7.1%$18.40+721.4%-68.8%$64.07M$10K-0.9010CUECue Biopharma1.336 of 5 stars$0.82-0.9%N/A+18.8%$63.47M$9.29M-1.4660High Trading Volume Related Companies and Tools Related Companies Opus Genetics Alternatives ZIVO Bioscience Alternatives Repare Therapeutics Alternatives MiNK Therapeutics Alternatives Coeptis Therapeutics Alternatives KALA BIO Alternatives MediciNova Alternatives Genenta Science Alternatives INmune Bio Alternatives Cue Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
